retatrutide safety study Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Helped Adults With Diabetes

This is where electrolytes become essential

Significant weight loss typically occurs between 3 to 6 months as the medication takes full effect

Accelerates recovery time

He stressed that many questions about GLP-1 medications remain, and there is a need for more research, such as identifying genotypes that are better matches for specific GLP-1 drugs, and reporting outcomes data in children

Currently, there are three FDA-approved oral GLP-1s on the market in the US: Rybelsus, which is approved for type 2 diabetes, the Wegovy pill, which is approved for weight loss, and Foundayo, which is also approved for weight loss